Form 8-K Ultragenyx Pharmaceutica For: Feb 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Wedbush Assumes Ultragenyx Pharma (RARE) at Outperform
February 17, 2017 12:09 PM ESTWedbush assumed coverage on Ultragenyx Pharma (NASDAQ: RARE) with an Outperform rating and a price target of $88.00.
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $76.82 yesterday.
... More


